**1. Introduction**

End-stage heart failure has an increasing incidence and prevalence worldwide. In Germany, 1 to 2% of the population suffers from chronic heart failure, with approximately 80,000 new cases per year. Cardiac transplantation has been the therapy of choice for patients with drug-resistant heart failure, but the decreasing number of donor organs leads to a significant prolongation of the waiting time for cardiac transplantation, resulting in an increased mortality of these patients [1, 2]. Indication of ventricular assistance device is for patients with advanced heart failure in whom maximum medical and surgical treatment has been exhausted. The purpose of ventricular assistance is twofold: first, to maintain circulation by discharging the ventricle (s) untill to recovery, and second, to ensure the survival of the patient by replacing the cardiac function, permanently or while waiting for a heart transplantation [3, 4].

The encouraging results of the partial or total artificial heart and the miniaturization of these devices make it possible to consider their use in permanent implantation for patients with heart failure who are not eligible for heart transplantation.

In left mono-ventricular assistance, the blood is taken through a cannula placed at the apex of the left ventricule (LV) and re-injected to the patient by a vascular prosthesis anastomosed to the ascending aorta. The classic surgical approach is a total midline sternotomy. Alternative minimally invasive approaches for implantation or explantation of left ventricular assist devices have been published and have shown encouraging results [5]. These alternatives currently play an important role in certain precise indications and in the most complex patients. Nevertheless, the complications after the implantation of mechanical assistance, even by a minimally invasive route, are still serious and can be lethal.

The impact of heart failure on individuals and society in general continues to grow. Heart transplantation remains the gold standard for treating patients with end-stage heart failure. The development of artificial hearts, partial and total, was mainly inspired by the disproportion between the number of available grafts and the number of candidates for heart transplantation. The significant technological advances made since Kolff's first work in 1957 allow these patients to return to their homes while awaiting the transplant. The encouraging results of the artificial heart and the miniaturization of these devices now make it possible to consider their use in permanent implantation for patients with heart failure who are not eligible for transplantation [6].

The objectives can be divided into two categories:


Implanted early enough in the course of the disease, ventricular assistance helps restore renal and hepatic functions, reduce pulmonary hypertension, mobilize excess interstitial fluid and prevent the onset of a multiorgan failure. Criteria for LVAD implantation are the persistence of the following settings despite maximum medical treatment:


**311**

surgery).

cachexia.

multidisciplinary consultation.

*Complications of Minimally Invasive Left Ventricular Assistance Device Implantation*

Assistance is contraindicated in active systemic infection, irreversible neurological impairment, and end-stage renal or hepatic failure. Severe peripheral vascular disease and haematological disorders are relative contraindications [12]. The aortic valve must be continent, otherwise the flow of assistance will flow back into the LV and dilate it. Severe pulmonary hypertension or right heart failure are a contraindication to left monoventricular assistance; in this case, biventricular

Of course, ventricular assistance is an expensive therapy. Long-term implanted

• 1st generation: extracorporeal pulsatile devices, often pneumatic, driven by an external console (Thoratec PVAD ™, Abiomed BVS 5000 ™); they are bulky

• 2nd generation: implantable pulsatile systems, most often electric (HeartMate

• 3rd generation: implantable axial flow systems, designed for long periods (HeartMate II ™, Jarvik 2000 ™, BerlinHeart ™); the only moving part is the rotor, valves are unnecessary; the latest models operate by magnetic levitation

HEARTMATE LVAD device is a mechanical, continuous flow, electrical, intracorporeal, monoventricular left circulatory device. This system is indicated when

• Indication in an acute situation: acute mono or biventricular failure in patients with heart failure, not controlled by optimal treatment, in the absence of a conventional therapeutic alternative (drug and / or intervention and/or

• Elective indication: advanced chronic heart failure with mono or biventricular failure, when life is threatened despite optimal treatment, and at the end of a

• severe pulmonary dysfunction and fixed pulmonary arterial hypertension.

• Documented irreversible central nervous system damage, recent stroke and

pumps (destination therapy) represent an expense of around € 220,000 [13].

Ventricular assist systems can be classified in three generations [3, 14]:

and contain many moving parts, including valves.

which eliminates the axes of the rotor, sources of wear.

the patient's body surface area is ≥1.2 m2 in the following situations:

The contraindications to HEARTMATE mechanical device are:

• Severe hepatic insufficiency (cirrhosis, portal hypertension, …).

• Major disorders of blood crass and uncontrolled bleeding.

• Uncontrolled systemic septic and inflammatory syndrome.

XVE ™, LionHeart ™, Thoratec IVAD ™).

*DOI: http://dx.doi.org/10.5772/intechopen.95638*

• Persistent metabolic acidosis.

assistance must be performed (20% of cases).

• diuresis <20 mL/hour.


*Complications of Minimally Invasive Left Ventricular Assistance Device Implantation DOI: http://dx.doi.org/10.5772/intechopen.95638*


Assistance is contraindicated in active systemic infection, irreversible neurological impairment, and end-stage renal or hepatic failure. Severe peripheral vascular disease and haematological disorders are relative contraindications [12]. The aortic valve must be continent, otherwise the flow of assistance will flow back into the LV and dilate it. Severe pulmonary hypertension or right heart failure are a contraindication to left monoventricular assistance; in this case, biventricular assistance must be performed (20% of cases).

Of course, ventricular assistance is an expensive therapy. Long-term implanted pumps (destination therapy) represent an expense of around € 220,000 [13]. Ventricular assist systems can be classified in three generations [3, 14]:


HEARTMATE LVAD device is a mechanical, continuous flow, electrical, intracorporeal, monoventricular left circulatory device. This system is indicated when the patient's body surface area is ≥1.2 m2 in the following situations:


The contraindications to HEARTMATE mechanical device are:


"HeartMate" is one of the continuous flow systems which are driven by an axial turbine (HeartMate ™ II, BerlinHeart ™, Jarvik 2000 ™, DeBakey MicroMed ™) or a centrifugal pump (HeartMate ™ III). They are implanted by sternotomy or thoracotomy. The blood is taken from the apex of the LV and returned to the ascending or descending aorta through a tubular prosthesis. The assured flow rate is 3 to 10 L/min. These simpler and quieter continuous flow systems are less prone to embolism and infections than pulsatile systems [14, 15]. In addition, they let the heart continue to eject which promotes its recovery.

**313**

**Figure 2.**

*Minimally invasive LVAD implantation approach.*

*Complications of Minimally Invasive Left Ventricular Assistance Device Implantation*

Their size is small, and they can be implanted in short patients. The arterial curve is practically flat, the systolic and diastolic blood pressure are the same as the Mean arteriel pressure. The functionality of the LV results in hooks added to this curve; these are all the more important as the LV performs better or the pump

The smaller design of the pump and its intrapericardial location has allowed the development of less invasive alternatives and implantation techniques. The technique of left ventricular assistance by minimally invasive approach has been described in several publications [5, 16–19]. It consists of an upper J-shaped mini-sternotomy or an anterior thoracotomy in the 2nd right intercostal space for access to the ascending aorta (site of anastomosis of the ejection voice) as well as to the right atrium (if atriocaval cannulation) and a left subcostal approach or a left anterolateral thoracotomy of 8 to 10 Cm for access to the apex of the heart and

According to Anson et al. [18], the use of small incisions allows exposure of the exact areas required for cannulation without the need for cardiac manipulation which is often poorly tolerated in these severe patients, and therefore implantation without cardiopulmonary bypass (CBP) becomes possible. In the study of Bantayehu Sileshi et al. [17] including 51 HeartWare implantations for patients waiting for heart transplantation, eighteen of them were with minimally invasive approach without CPB. The choice of the surgical technique was made by a multidisciplinary committee, taking into consideration the contraindications, in particular the respiratory one, for thoracotomy. Univariate analysis revealed a statistically significant reduction in the duration of treatment with inotropic drugs (p = 0.04), and reduced intraoperative

*DOI: http://dx.doi.org/10.5772/intechopen.95638*

implantation of the device (**Figure 1** and **2**).

output decreases.

**Figure 1.** *LVAD device.*

*Complications of Minimally Invasive Left Ventricular Assistance Device Implantation DOI: http://dx.doi.org/10.5772/intechopen.95638*

Their size is small, and they can be implanted in short patients. The arterial curve is practically flat, the systolic and diastolic blood pressure are the same as the Mean arteriel pressure. The functionality of the LV results in hooks added to this curve; these are all the more important as the LV performs better or the pump output decreases.

The smaller design of the pump and its intrapericardial location has allowed the development of less invasive alternatives and implantation techniques. The technique of left ventricular assistance by minimally invasive approach has been described in several publications [5, 16–19]. It consists of an upper J-shaped mini-sternotomy or an anterior thoracotomy in the 2nd right intercostal space for access to the ascending aorta (site of anastomosis of the ejection voice) as well as to the right atrium (if atriocaval cannulation) and a left subcostal approach or a left anterolateral thoracotomy of 8 to 10 Cm for access to the apex of the heart and implantation of the device (**Figure 1** and **2**).

According to Anson et al. [18], the use of small incisions allows exposure of the exact areas required for cannulation without the need for cardiac manipulation which is often poorly tolerated in these severe patients, and therefore implantation without cardiopulmonary bypass (CBP) becomes possible. In the study of Bantayehu Sileshi et al. [17] including 51 HeartWare implantations for patients waiting for heart transplantation, eighteen of them were with minimally invasive approach without CPB. The choice of the surgical technique was made by a multidisciplinary committee, taking into consideration the contraindications, in particular the respiratory one, for thoracotomy. Univariate analysis revealed a statistically significant reduction in the duration of treatment with inotropic drugs (p = 0.04), and reduced intraoperative

**Figure 2.** *Minimally invasive LVAD implantation approach.*

blood transfusion (p = 0.08) in minimally invasive implantations. Conversly, there was no difference regarding the duration of intensive care stay (p = 0.5), the total intra-hospital saty (p = 0.76) and the total time of mechanical ventilation (p = 0.32). There were four in-hospital deaths and three stroke complications all were operated on by sternotomy under CBP. Authors showd also an increasing risk of infection, bleeding and redo-sternotomy complications at the time of heart transplantation [20].

Less invasive surgical approaches have been developed with the hope of reducing CPB time and operative trauma, minimizing perioperative blood loss, protecting cardiac structures from multiple re-entries, and preserving the heart geometry [21].

Haberl and al. recently described their clinical experience in minimally invasive implantation for HeartWare and HeartMate II [22]. Of the 27 patients in their study, 5 (19%) were performed without CPB. They had a reported in-hospital mortality of 14.8%, and an average hospital stay of 30 days. They concluded that minimally invasive LVAD implantation is feasible and safe. Moreover, Anelechi C [5] thinks that this technique is inadequate for patients who have previously had cardiac surgery without giving any arguments.

Minimally invasive approach was also recommended for the device remove or changing [23–27]. For example, the team of Igor D. Gregoric [23] showed the superiority of the subcostal route alone to change HeartMate XVE by HeratMate II compared to sternotomy with left subcostal approach in terms of transfusion, operative duration and postoperative stay. The same results were found in the study of John m. Stulak and his colleagues [26].
